Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 9/20 | 0.37 |
| ▸ | PSEN2 | P49810 | 9/20 | 0.37 |
| ▸ | APH1B | Q8WW43 | 9/20 | 0.37 |
| ▸ | NCSTN | Q92542 | 9/20 | 0.37 |
| ▸ | APH1A | Q96BI3 | 9/20 | 0.37 |
| ▸ | PSENEN | Q9NZ42 | 9/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.35 |
| ▸ | REN | P00797 | 3/20 | 0.34 |
| ▸ | NMBR | P28336 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 2/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30343346 | 0.97 | PSEN1 (0.36) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL30250211 | 0.96 | OPRD1 (0.36) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL30524338 | 0.96 | PSEN1 (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL30384193 | 0.95 | ACE (0.37) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL30437554 | 0.94 | PSEN1 (0.37) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL30863518 | 0.94 | PSEN1 (0.39) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL34461946 | 0.90 | REN (0.39) | OPRD1REN | |
| SCHEMBL34461945 | 0.90 | REN (0.40) | OPRD1REN | |
| SCHEMBL31614440 | 0.89 | REN (0.41) | OPRD1REN | |
| SCHEMBL31094168 | 0.89 | REN (0.38) | OPRD1RENNMBRCTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116693653-B | Preparation method for large-scale production of somalupeptide | 杭州湃肽生化科技有限公司 | 2023-10-31 | — | — | CN | claimed |
| US-20250188118-A1 | LIQUID PHASE PEPTIDE SYNTHESIS METHODS | AMGEN INC. (US) | 2025-06-12 | — | — | US | disclosed |
| CN-116693653-B | Preparation method for large-scale production of somalupeptide | 杭州湃肽生化科技有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116693653-A | Preparation method for large-scale production of somalupeptide | 杭州湃肽生化科技有限公司 | 2023-09-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188118-A1 | LIQUID PHASE PEPTIDE SYNTHESIS METHODS | VIP, RNGTT, SSU72 | PSEN1 4016/4885PSEN2 3624/4885APH1B 3259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.